The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

Life sciences consulting firm Parexel is teaming up with Sanofi to research the role of wearables in clinical trials. While sensor-enabled devices have increasingly featured in a variety of research ...

QuantHealth's AI-powered clinical simulator predicts how an individual in a clinical trial will respond to treatment. The aim is to assist pharmaceutical companies in improving their clinical trial ...

Prices displayed are informational. Learn more Recursion Pharmaceuticals (RXRX) said Thursday it priced an offering of 61.5 million shares at $3.25 each to raise gross proceeds of about $200 million.

TEL AVIV, Isreal & CAMBRIDGE, Mass., October 01, 2025--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the ...

Sanofi’s rare disease drug venglustat has met the primary endpoint in a Phase III trial in Gaucher disease but missed the same achievement in a Phase III trial in Fabry disease. In the LEAP2MONO trial ...

KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a ...

(RTTNews) - Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry, announced an extension of its strategic partnership with Sanofi.